Incyte Corporation (INCY) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Biotechnology
Wait for pullback to $90.06. At $96.53 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $90.06 (R/R-minimum solve) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: JAKAFI; Analyst target reached - limited upside remaining.
Incyte is a global biopharmaceutical company with approved products in Hematology (JAKAFI, ICLUSIG, MONJUVI/MINJUVI, NIKTIMVO), Oncology (PEMAZYRE, ZYNYZ), and Inflammation & Autoimmunity (OPZELURA), headquartered in Wilmington, Delaware with operations in Europe, Japan, and... Read more
Wait for pullback to $90.06. At $96.53 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $90.06 (R/R-minimum solve) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: JAKAFI; Analyst target reached - limited upside remaining. Chart setup: RSI 55 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.36, quality 8.5/10, growth 8.8/10). Score 6.8/10, high confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 69d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Incyte Corporation
Latest news
- Stronger Q1 Earnings And New CFO Might Change The Case For Investing In Incyte (INCY) - Sahm — Sahm positive
- Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch — MarketWatch positive
- Stifel raises Incyte stock price target to $123 on earnings beat By Investing.com - Investing.com South Africa — Investing.com South Africa positive
- Stifel raises Incyte stock price target to $123 on earnings beat - Investing.com — Investing.com positive
- Stifel raises Incyte stock price target to $123 on earnings beat - Investing.com Canada — Investing.com Canada positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductJAKAFI10-K Item 1A: 'We depend heavily on JAKAFI/JAKAVI (ruxolitinib), and if we are not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, our business may be materially harmed'
Material Events(8-K, last 90d)
- 2026-03-30Item 5.02LOWSusanne Schaffert, a board director since 2022, notified Incyte of her resignation effective April 15, 2026. Resignation not the result of any disagreement with the Company. No successor named.SEC filing →
- 2026-03-26Item 5.02LOWIncyte announced title changes: Pablo Cagnoni becomes President; Steven Stein becomes EVP/CMO; Mohamed Issa becomes EVP/Head of US Commercial. William Meury remains CEO. No compensation changes in connection with title changes.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $90.06. At $96.53 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $90.06 (R/R-minimum solve) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: JAKAFI; Analyst target reached - limited upside remaining. Chart setup: RSI 55 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.36, quality 8.5/10, growth 8.8/10). Target $97.65 (+1.2%), stop $85.00 (−13.6%), Setup A.R:R 1.5:1. Score 6.8/10, high confidence.
Take-profit target: $97.65 (+8.4% upside). Target $97.65 (+1.2%), stop $85.00 (−13.6%), Setup A.R:R 1.5:1. Stop-loss: $85.00.
Concentration risk — Product: JAKAFI; Analyst target reached - limited upside remaining; Negative momentum.
Incyte Corporation trades at a P/E of 13.5 (forward 10.6). TrendMatrix value score: 7.8/10. Verdict: Buy (Wait for Entry).
33 analysts cover INCY with a consensus score of 3.7/5. Average price target: $109.
What does Incyte Corporation do?Incyte is a global biopharmaceutical company with approved products in Hematology (JAKAFI, ICLUSIG, MONJUVI/MINJUVI,...
Incyte is a global biopharmaceutical company with approved products in Hematology (JAKAFI, ICLUSIG, MONJUVI/MINJUVI, NIKTIMVO), Oncology (PEMAZYRE, ZYNYZ), and Inflammation & Autoimmunity (OPZELURA), headquartered in Wilmington, Delaware with operations in Europe, Japan, and Canada. Revenue is heavily dependent on JAKAFI (ruxolitinib) royalties and US sales. A small number of specialty pharmacies and wholesalers represent a significant portion of JAKAFI revenues.